Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 5301 - 5325 of 5888 in total

[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid

Experimental

3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide

Experimental

Nafamostat

Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing...
Investigational

3-[(1-Amino-2-Carboxy-Ethyl)-Hydroxy-Phosphinoyl]-2-Methyl-Propionic Acid

Experimental

(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine

Experimental

(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID

Experimental

N-Methylphenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide

Experimental

Tamatinib

Experimental
Investigational

Anlotinib

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
Investigational

ONCOS‐102

Investigational

Cemdomespib

Cemdomespib is under investigation in clinical trial NCT05895552 (A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS)).
Investigational

Ethyl loflazepate

Experimental
Illicit

Dezapelisib

Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).
Investigational

Empegfilgrastim

Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).
Investigational

1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL

Experimental

(2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide

Experimental

Arimoclomol

Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational

Sebetralstat

Investigational

Tirabrutinib

Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).
Investigational

TBI-223

TBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).
Investigational

8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine

Experimental

N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-

Experimental

Azenosertib

Investigational

Etoposide toniribate

Investigational

Deucrictibant

Investigational
Displaying drugs 5301 - 5325 of 5888 in total